Assessment Of Safety Of UK-390,957
Phase 2
Completed
- Conditions
- Ejaculation
- Registration Number
- NCT00219609
- Lead Sponsor
- Pfizer
- Brief Summary
To determine whether UK-390,957 is a safe treatment for premature ejaculation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 1058
Inclusion Criteria
- Subjects will have completed one of the phase 2 trials (A3871022/ A3871027/ A3871029) and will have met the diagnostic criteria for premature ejaculation as defined by DSM-IV
Exclusion Criteria
- No drug related serious adverse events
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Assessment of safety
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie UK-390,957's action on ejaculatory control pathways?
How does UK-390,957 compare to SSRIs like dapoxetine in treating premature ejaculation safety profiles?
Are there specific biomarkers that correlate with UK-390,957 treatment response in premature ejaculation patients?
What are the long-term adverse event profiles of UK-390,957 in adult male populations?
What related compounds or combination therapies are being explored for premature ejaculation alongside UK-390,957?
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇬🇧Devon, United Kingdom
Pfizer Investigational Site🇬🇧Devon, United Kingdom